EUVIMEDEUVIMED entdecken
Open Access

Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?

Risa M Wolf iD, Dhruva Patel, Sonia Gera, Grace Molano, Tawni Dolivera, Seema Meighan iD, Elizabeth A Brown, Brynn E Marks iD

Diabetes Technology & Therapeutics · 2025

DOI: 10.1089/dia.2024.0612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2025. Verfasst von Risa M Wolf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Endocrinology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Black or African American, Diabetes Mellitus, Type 1, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of automated insulin delivery (AID) systems improves glycemic control, however, racial and ethnic disparities in glycemic control among youth with type 1 diabetes (T1D) persist. We studied whether the Omnipod 5 (OP5) AID system could close gaps in glycemia between White and Black youth with T1D.

Methods

This retrospective longitudinal analysis compared matched pairs of White and Black youth with T1D using OP5 at two pediatric academic centers. In unadjusted and adjusted models, we assessed changes in the gap in time in range (TIR), average continuous glucose monitor (CGM) glucose, and hemoglobin A1c (HbA1c) between White and Black youth from baseline to 9 days and 90 days.

Results

Matched pairs ( n = 132) of White and Black youth using OP5 (61% female, mean age 11.6 years, 40% publicly insured, median T1D duration 2.9 years, mean HbA1c 8.6%) were included. Within 9 days of OP5 use, the baseline TIR gap of 7.8% points decreased to 3.9% points ( P = 0.052), and the average CGM glucose gap of 20.5mg/dL at baseline decreased to 8.0 mg/dL ( P = 0.012), demonstrating a reduction in the gap between groups. At 90 days, there was no significant reduction in gap from baseline for TIR ( P = 0.35) or CGM glucose ( P = 0.09). When adjusting for insurance and baseline insulin delivery method, there was no significant reduction in gaps at either 9 days or 90 days. All youth had decreases in HbA1c. At 90 days, time in automated mode (88% vs. 94%, P < 0.0001) and boluses per day (3.9 vs. 5.3, P < 0.0001) were lower in Black youth. In multivariable analysis, youth transitioning to OP5 from multiple daily injections had the greatest increases in TIR at 9 days ( P < 0.001) and at 90 days ( P < 0.01).

Conclusions

Gaps in TIR and average CGM glucose between White and Black youth narrow with AID use, but do not close completely. Equitable access to AID should be encouraged for all youth, however, differences in AID interaction emphasize the need for additional interventions to overcome social determinants of health that likely explain the inability of diabetes technology to fully close the gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Black or African AmericanDiabetes Mellitus, Type 1Glycemic ControlHypoglycemic AgentsInsulinInsulin Infusion SystemsWhiteAdolescentChildFemaleHumansMaleBlood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinLongitudinal StudiesRetrospective StudiesWhite PeopleHealth Status Disparities

Stichwörter der Autor:innen

automated insulin deliverybarriersglycemic controlinequitiesminority youthtype 1 diabetes

Substanzen

Blood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Endocrinology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Perelman School of Medicine, the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Risa M Wolf, Seema Meighan, Brynn E Marks

Förderung

  • NIDDK NIH HHS
  • NEI NIH HHS

Zitieren

APA

Wolf, R. M., Patel, D., Gera, S., Molano, G., Dolivera, T., Meighan, S., Brown, E. A., & Marks, B. E. (2025). Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2024.0612

Vancouver

Wolf RM, Patel D, Gera S, Molano G, Dolivera T, Meighan S, et al. Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?. Diabetes Technology & Therapeutics. 2025. doi:10.1089/dia.2024.0612

BibTeX
@article{Wolf2025,
  author = {Wolf, Risa M and Patel, Dhruva and Gera, Sonia and Molano, Grace and Dolivera, Tawni and Meighan, Seema and Brown, Elizabeth A and Marks, Brynn E},
  title = {Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?},
  journal = {Diabetes Technology & Therapeutics},
  year = {2025},
  doi = {10.1089/dia.2024.0612}
}
Kostenlos starten →